Literature DB >> 21037129

Increased cortisol levels and anticholinergic activity in cognitively unimpaired patients.

Konstanze Plaschke1, Jürgen Kopitz, Johannes Mattern, Eike Martin, Peter Teschendorf.   

Abstract

Increased patients' serum anticholinergic activity (SAA) is described as a marker of cognitive dysfunction and can be influenced by different exogenous and endogenous factors. The role of cortisol in relation to SAA and cognition in perioperative conditions has not been investigated so far. In 30 men scheduled for urological surgery, the authors determined SAA and cortisol levels in blood and CSF and conducted neuropsychological testing in two subgroups with comparable pre- and intraoperative characteristics, one group with low SAA (mean=2.4 [SD=0.9], n=23) and the other with high SAA (mean=5.1 [SD=2.4], n=7) values. Increased SAA was associated with two times the number of anticholinergic medications but not with patients' age, medical history or impaired cognition. A significant linear correlation was detected between anticholinergic activities and cortisol levels. Thus, endogenous factors such as patients' stress levels should be taken into account for interpretation of the role of SAA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21037129     DOI: 10.1176/jnp.2010.22.4.433

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  7 in total

1.  Central Anticholinergic Adverse Effects and Their Measurement.

Authors:  Pasi Lampela; Teemu Paajanen; Sirpa Hartikainen; Risto Huupponen
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

2.  Differentiation between genomic and non-genomic feedback controls yields an HPA axis model featuring hypercortisolism as an irreversible bistable switch.

Authors:  Clemens A Zarzer; Martin G Puchinger; Gottfried Köhler; Philipp Kügler
Journal:  Theor Biol Med Model       Date:  2013-11-09       Impact factor: 2.432

Review 3.  Mini Review: Anticholinergic Activity as a Behavioral Pathology of Lewy Body Disease and Proposal of the Concept of "Anticholinergic Spectrum Disorders".

Authors:  Koji Hori; Kimiko Konishi; Misa Hosoi; Hiroi Tomioka; Masayuki Tani; Yuka Kitajima; Mitsugu Hachisu
Journal:  Parkinsons Dis       Date:  2016-09-22

4.  Temporal biomarker profiles and their association with ICU acquired delirium: a cohort study.

Authors:  Koen S Simons; Mark van den Boogaard; Eva Hendriksen; Jelle Gerretsen; Johannes G van der Hoeven; Peter Pickkers; Cornelis P C de Jager
Journal:  Crit Care       Date:  2018-05-25       Impact factor: 9.097

Review 5.  Serum anticholinergic activity: a possible peripheral marker of the anticholinergic burden in the central nervous system in Alzheimer's disease.

Authors:  Koji Hori; Kimiko Konishi; Masayuki Tani; Hiroi Tomioka; Ryo Akita; Yuka Kitajima; Mari Aoki; Sachiko Yokoyama; Kazunari Azuma; Daisuke Ikuse; Norihisa Akashi; Misa Hosoi; Koichi Jinbo; Mitsugu Hachisu
Journal:  Dis Markers       Date:  2014-02-09       Impact factor: 3.434

Review 6.  Serum Anticholinergic Activity and Cognitive and Functional Adverse Outcomes in Older People: A Systematic Review and Meta-Analysis of the Literature.

Authors:  Mohammed Saji Salahudeen; Te-Yuan Chyou; Prasad S Nishtala
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

Review 7.  Anticholinergic Drugs in Geriatric Psychopharmacology.

Authors:  Jorge López-Álvarez; Julia Sevilla-Llewellyn-Jones; Luis Agüera-Ortiz
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.